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ABSTRACT  
 
We present the case of a 2-month-old infant with reticular dysgenesis who was treated 
with recombinant granulocyte-macrophage colony stimulating factor with the aim of 
stimulating granulopoiesis while awaiting bone marrow transplant. 
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ABBREVIATIONS  
 
 BMT bone marrow transplant   
 RD reticular dysgenesis  
 rG-CSF recombinant granulocyte stimulating factor 
 rGM-CSF Recombinant granulocyte-macrophage stimulating factor WBC white 
blood cells 
  
 
 
INTRODUCTION 
 
Reticular dysgenesis (RD) is a rare congenital disorder classified within the severe 
combined immunodeficiencies, characterized by impaired development of multiple 
haematopoietic cell lineages. In addition to the early developmental failure of both T- 
and B-cell lineages, growth and differentiation of myeloid cells is impaired in affected 
newborns. To date, bone marrow transplantation (BMT) is the only treatment [3], 
suggesting that RD may reflect an inherited defect shared by myeloid and lymphoid cell 
precursors. It has been demonstrated that recombinant granulocyte-monocyte colony-
stimulating factor (rGM-CSF) is a potent stimulator of myelopoiesis in vivo in patients 
with acquired immunodeficiency syndrome, myelodysplastic syndromes, aplastic 
anaemia, lymphoproliferative disorders, acquired agranulocytosis, and in patients who 
have received chemotherapy or autologous BMT [4]. In an attempt to stimulate 
granulopoiesis, our patient was treated with rGM-CSF while awaiting a BMT. We 
observed a positive response at the beginning of the treatment. 
  
 
CASE REPORT  
 
A 2-month-old white male newborn from non-consanguineous parents was diagnosed as 
having RD at 1 month of age. There was no particular relevant family history except for 
recurrent furunculosis in his mother. He had a healthy sister. He presented with fever, 
leucopenia, neutropenia and diarrhoea during his 1
st
 month of life. He suffered from a 
dilated cardiomyopathy. At 1 month of age the total white blood cell count (WBC) was 
0.92 x 10
9
/1 (0.115 x 10
9
/1 neutrophils, 0.4 x 10
9
/1 lymphocytes and 0.41 x 10
9
/1 
monocytes). He had hypogammaglobulinaemia (Ig G 126 mg%, Ig A 3.5 mg%, Ig M 5 
mg%). Forssman antibodies and the isohaemagglutinins were negative. A bone marrow 
examination showed almost total absence of myeloid series cells with some cells 
resembling lymphoblasts. However, cells of erythroid and megakaryocytic origin were 
present at all stages of maturation. Bone marrow immunophenotype was: A1, A11, B8, 
B18, BW6, DR3, DRW52. Peripheral blood lymphocyte phenotype was as follows: 
CD3 18%, CD4 15%, CD8 1%, CD19 41%, CD20 51%, DR 42%, CD10 35%, CD44%, 
CD16 10%. The erythrocyte enzymes adenosindeaminase and purine nucleoside 
phosphorylase were positive, TdT was negative. Human immunodeficiency virus 
antibodies were negative. Lymphoid proliferation mitogen tests were negative. 
Postmortem we could prove that the thymic gland was hypoplastic, showing a lymphoid 
depletion which was also seen in other lymphatic organs (spleen, nodes and lymphoid 
mucosal tissues). These results were consistent with a diagnosis of severe combined 
immunodeficiency due to reticular dysgenesis. 
 
While a suitable donor was being sought within the family in order to perform a BMT, 
the patient was treated with rGM-CSF given by intravenous infusion (in 1 h). The initial 
dose was 4 µg/kg per day increasing progressively up to a maximum dose of 15 µg/kg 
per day on day 15 of treatment. Then, owing to adverse effects (vomiting related to 
dose) we decreased the dose to 10 µg/kg per day until the 20
th
 day of treatment, as is 
shown in Fig. 1. The total WBC increased from 0.92 x 10
9
/1 (24% neutrophils) to 1.9 x 
10
9
/1 (52.9% neutrophils) on the 10
th
 day of treatment. On the 15
th
 day, the WBC was 
1.6 x 10
9
/1 (51% neutrophils). Twelve days after finishing the treatment, we observed a 
decrease in the WBC. For this reason we decided to reintroduce the treatment at the 
final dose given during the first phase of the treatment; in this second period we 
observed no marked modification in the leucocytes, except for an increase in the 
number of eosinophils, and the treatment was discontinued on the 23
rd
 day. During the 
treatment we did not observe any severe side-effects. The patient presented: arterial 
hypertension during the 1
st
 and 2
nd
 day of treatment related to the time of infusion, and 
vomiting, which started at the 2
nd
 day of treatment and increased relative to the dose. 
During this second phase the patient suffered a further deterioration due to severe 
infections caused by cytomegalovirus and Aspergillus fumigatus which caused his death 
at the age of 5 months. 
DISCUSSION 
 
In most cases of idiopathic congenital neutropenia, rGM-CSF increases the number of 
functional leucocytes, due mainly to eosinophils [5, 6,]. However most children with 
congenital neuropenia treated with recombinant granulocyte stimulating factor (rG-
CSF) have responded with a large increase in the number of functional neutrophils [1, 
6]. In contrast, Bujan et al. [2], did not meet with a positive response when applying rG-
CSF to a patient with RD. In an attempt to stimulate granulopoiesis and to prevent a 
clinical deterioration while expecting to perform a BMT, we decided to administer 
rGM-CSF to our patient. Treatment with rGM-CSF in this case elicited leucocytes 
consisting primarily of neutrophils and lymphocytes in the first period to treatment. A 
marked eosinophilia was observed at the beginning of the second phase of treatment. 
 
This moderately good response in our patient suggests that the haematopoietic precursor 
common to both myeloid and lymphoid origin is more sensitive to GM-CSF than to G-
CSF. As has recently been stated by Bujan et al. [2], treatment of such patients with a 
growth factor which acts at an earlier stage would be of interest. We should like to 
suggest the possibility of giving this myelopoietic factor or an earlier acting factor (IL-
3) in patients suffering from severe combined immunodeficiency in order to prevent 
clinical deterioration while searching for a suitable donor for BMT, or waiting for the 
resolution of a temporary problem that rules out BMT. 
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Figure 1. Effects of rGM-CSF treatment on leucocytes, neutrophils and platelets. 
 
 
 
 
 
